《降低通胀法案》：对 Medicare 支出以及生物疗法在伴有鼻息肉和哮喘的慢性鼻-鼻窦炎中的可及性的影响。
The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma.
机构信息
Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Department of Surgery, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA.
出版信息
Int Forum Allergy Rhinol. 2024 Jul;14(7):1261-1265. doi: 10.1002/alr.23344. Epub 2024 Mar 11.
In 2021, Medicare spending on biologics was $926 million in Part B (FFS) and $1.3 billion in Part D (FFS/MA). Between 2017 and 2021, annual Medicare spending on biologics increased by approximately 200%. Between 2023 and 2025, Medicare Part D OOP costs for biologics will decrease by an estimated 50%-60%.
2021 年，医疗保险生物制剂在 B 部分（FFS）的支出为 9.26 亿美元，在 D 部分（FFS/MA）的支出为 13 亿美元。2017 年至 2021 年间，医疗保险生物制剂的年度支出增长了约 200%。在 2023 年至 2025 年期间，医疗保险 D 部分的生物制剂自付费用预计将减少 50%-60%。
Zotero 插件